2006
Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition
Brown NJ, Muldowney JA, Vaughan DE. Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition. Hypertension 2006, 47: 441-448. PMID: 16432054, DOI: 10.1161/01.hyp.0000202478.79587.1a.Peer-Reviewed Original ResearchMeSH KeywordsAdultAldosteroneAngiotensin-Converting Enzyme InhibitorsArginineDouble-Blind MethodDrug CombinationsEnzyme InhibitorsFemaleFibrinolysisHemodynamicsHumansInfusions, IntravenousMaleMiddle AgedNG-Nitroarginine Methyl EsterNitric OxideNitric Oxide SynthasePlasminogen Activator Inhibitor 1ProdrugsRamiprilReference ValuesRenin-Angiotensin SystemConceptsPlasminogen activator inhibitor-1Plasminogen activator inhibitor-1 antigenActivator inhibitor-1Salt-replete subjectsL-arginineFibrinolytic balanceInhibitor-1Angiotensin-Converting Enzyme InhibitionNO precursor L-argininePlasminogen activator inhibitor antigenTissue-type plasminogen activator antigenEffect of angiotensinPrecursor L-argininePlasminogen activator antigenNO synthase inhibitorEnzyme inhibitionT-PA activityRenin activityD-dimerInhibitor antigenNormal subjectsSynthase inhibitorEnzyme inhibitorsT-PAAntigen
2004
NO Synthase Inhibition Increases Aldosterone in Humans
Muldowney JA, Davis SN, Vaughan DE, Brown NJ. NO Synthase Inhibition Increases Aldosterone in Humans. Hypertension 2004, 44: 739-745. PMID: 15381675, DOI: 10.1161/01.hyp.0000143852.48258.f1.Peer-Reviewed Original ResearchConceptsL-NAME infusionL-NAMEL-arginineAldosterone concentrationSerum potassiumNitro-L-arginine methyl esterNO precursor L-arginineEndogenous NO modulatesDouble-blind treatmentPlasma renin activityAngiotensin II concentrationEnzyme inhibitor ramiprilSystolic blood pressurePrecursor L-arginineRenin activityPlacebo pretreatmentBlood pressureSerum aldosteroneTreatment armsNO modulatesVehicle infusionHeart rateNormal subjectsSeparate daysCombined treatment
1991
A pharmacodynamic interaction between caffeine and phenylpropanolamine
Brown N, Ryder D, Branch R. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clinical Pharmacology & Therapeutics 1991, 50: 363-371. PMID: 1914371, DOI: 10.1038/clpt.1991.152.Peer-Reviewed Original ResearchConceptsBlood pressurePharmacodynamic interactionsPlasma renin activityRenin-angiotensin systemDrug-free subjectsCoadministration of caffeineRenin responseRenin activityPharmacokinetic interactionsCatecholamine levelsSupine positionNormal subjectsLatin square design studyDrug AdministrationRandom orderPhenylpropanolamineMetabolite levelsPlaceboCaffeineSubjectsAdditive increaseHoursCoadministrationEpinephrineAdministrationCaffeine potentiates the renin response to diazoxide in man. Evidence for a regulatory role of endogenous adenosine.
Brown NJ, Porter J, Ryder D, Branch RA. Caffeine potentiates the renin response to diazoxide in man. Evidence for a regulatory role of endogenous adenosine. Journal Of Pharmacology And Experimental Therapeutics 1991, 256: 56-61. PMID: 1988669.Peer-Reviewed Original ResearchConceptsRenin responseEndogenous adenosineRenin releaseDiazoxide infusionAdenosine inhibitsRegulation of reninCross-over studyAdministration of diazoxideAdenosine receptor blockerModest tachycardiaPRA responseReceptor blockersBP responseLoading dosePRA measurementsContinuous infusionNormal subjectsStudy daysDiazoxideMaximal pulseInfusionPresence of caffeineReninCaffeineAdenosine